-
Je něco špatně v tomto záznamu ?
Enhanced drug delivery by a prodrug approach effectively relieves neuroinflammation in mice
AB. Montaser, J. Kuiri, T. Natunen, P. Hruška, D. Potěšil, S. Auriola, M. Hiltunen, T. Terasaki, M. Lehtonen, A. Jalkanen, KM. Huttunen
Jazyk angličtina Země Nizozemsko
Typ dokumentu časopisecké články
- MeSH
- antiflogistika nesteroidní * farmakologie MeSH
- intracelulární signální peptidy a proteiny metabolismus MeSH
- kyselina salicylová farmakologie MeSH
- lipopolysacharidy MeSH
- mikroglie metabolismus MeSH
- myši inbrední C57BL MeSH
- myši MeSH
- neurodegenerativní nemoci * metabolismus MeSH
- neurozánětlivé nemoci * farmakoterapie MeSH
- prekurzory léčiv * farmakologie MeSH
- proteom metabolismus MeSH
- zánět farmakoterapie metabolismus MeSH
- zvířata MeSH
- Check Tag
- myši MeSH
- zvířata MeSH
- Publikační typ
- časopisecké články MeSH
AIMS: Neuroinflammation is a prominent hallmark in several neurodegenerative diseases (NDs). Halting neuroinflammation can slow down the progression of NDs. Improving the efficacy of clinically available non-steroidal anti-inflammatory drugs (NSAIDs) is a promising approach that may lead to fast-track and effective disease-modifying therapies for NDs. Here, we aimed to utilize the L-type amino acid transporter 1 (LAT1) to improve the efficacy of salicylic acid as an example of an NSAID prodrug, for which brain uptake and intracellular localization have been reported earlier. MAIN METHODS: Firstly, we confirmed the improved LAT1 utilization of the salicylic acid prodrug (SA-AA) in freshly isolated primary mouse microglial cells. Secondly, we performed behavioural rotarod, open field, and four-limb hanging tests in mice, and a whole-brain proteome analysis. KEY FINDINGS: The SA-AA prodrug alleviated the lipopolysaccharide (LPS)-induced inflammation in the rotarod and hanging tests. The proteome analysis indicated decreased neuroinflammation at the molecular level. We identified 399 proteins linked to neuroinflammation out of 7416 proteins detected in the mouse brain. Among them, Gps2, Vamp8, Slc6a3, Slc18a2, Slc5a7, Rgs9, Lrrc1, Ppp1r1b, Gnal, and Adcy5/6 were associated with the drug's effects. The SA-AA prodrug attenuated the LPS-induced neuroinflammation through the regulation of critical pathways of neuroinflammation such as the cellular response to stress and transmission across chemical synapses. SIGNIFICANCE: The efficacy of NSAIDs can be improved via the utilization of LAT1 and repurposed for the treatment of neuroinflammation. This improved brain delivery and microglia localisation can be applied to other inflammatory modulators to achieve effective and targeted CNS therapies.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc22032365
- 003
- CZ-PrNML
- 005
- 20230131151559.0
- 007
- ta
- 008
- 230120s2022 ne f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.lfs.2022.121088 $2 doi
- 035 __
- $a (PubMed)36257461
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a ne
- 100 1_
- $a Montaser, Ahmed B $u School of Pharmacy, Faculty of Health Sciences, University of Eastern Finland, P.O. Box 1627, FI-70211 Kuopio, Finland. Electronic address: ahmed.montaser@uef.fi
- 245 10
- $a Enhanced drug delivery by a prodrug approach effectively relieves neuroinflammation in mice / $c AB. Montaser, J. Kuiri, T. Natunen, P. Hruška, D. Potěšil, S. Auriola, M. Hiltunen, T. Terasaki, M. Lehtonen, A. Jalkanen, KM. Huttunen
- 520 9_
- $a AIMS: Neuroinflammation is a prominent hallmark in several neurodegenerative diseases (NDs). Halting neuroinflammation can slow down the progression of NDs. Improving the efficacy of clinically available non-steroidal anti-inflammatory drugs (NSAIDs) is a promising approach that may lead to fast-track and effective disease-modifying therapies for NDs. Here, we aimed to utilize the L-type amino acid transporter 1 (LAT1) to improve the efficacy of salicylic acid as an example of an NSAID prodrug, for which brain uptake and intracellular localization have been reported earlier. MAIN METHODS: Firstly, we confirmed the improved LAT1 utilization of the salicylic acid prodrug (SA-AA) in freshly isolated primary mouse microglial cells. Secondly, we performed behavioural rotarod, open field, and four-limb hanging tests in mice, and a whole-brain proteome analysis. KEY FINDINGS: The SA-AA prodrug alleviated the lipopolysaccharide (LPS)-induced inflammation in the rotarod and hanging tests. The proteome analysis indicated decreased neuroinflammation at the molecular level. We identified 399 proteins linked to neuroinflammation out of 7416 proteins detected in the mouse brain. Among them, Gps2, Vamp8, Slc6a3, Slc18a2, Slc5a7, Rgs9, Lrrc1, Ppp1r1b, Gnal, and Adcy5/6 were associated with the drug's effects. The SA-AA prodrug attenuated the LPS-induced neuroinflammation through the regulation of critical pathways of neuroinflammation such as the cellular response to stress and transmission across chemical synapses. SIGNIFICANCE: The efficacy of NSAIDs can be improved via the utilization of LAT1 and repurposed for the treatment of neuroinflammation. This improved brain delivery and microglia localisation can be applied to other inflammatory modulators to achieve effective and targeted CNS therapies.
- 650 _2
- $a zvířata $7 D000818
- 650 _2
- $a myši $7 D051379
- 650 12
- $a antiflogistika nesteroidní $x farmakologie $7 D000894
- 650 _2
- $a zánět $x farmakoterapie $x metabolismus $7 D007249
- 650 _2
- $a intracelulární signální peptidy a proteiny $x metabolismus $7 D047908
- 650 _2
- $a lipopolysacharidy $7 D008070
- 650 _2
- $a myši inbrední C57BL $7 D008810
- 650 _2
- $a mikroglie $x metabolismus $7 D017628
- 650 12
- $a neurodegenerativní nemoci $x metabolismus $7 D019636
- 650 12
- $a neurozánětlivé nemoci $x farmakoterapie $7 D000090862
- 650 12
- $a prekurzory léčiv $x farmakologie $7 D011355
- 650 _2
- $a proteom $x metabolismus $7 D020543
- 650 _2
- $a kyselina salicylová $x farmakologie $7 D020156
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Kuiri, Janita $u School of Pharmacy, Faculty of Health Sciences, University of Eastern Finland, P.O. Box 1627, FI-70211 Kuopio, Finland
- 700 1_
- $a Natunen, Teemu $u Institute of Biomedicine, School of Medicine, University of Eastern Finland, P.O. Box 1627, FI-70211 Kuopio, Finland
- 700 1_
- $a Hruška, Pavel $u Central European Institute of Technology, Masaryk University, Kamenice 5, 62500 Brno, Czech Republic
- 700 1_
- $a Potěšil, David $u Central European Institute of Technology, Masaryk University, Kamenice 5, 62500 Brno, Czech Republic
- 700 1_
- $a Auriola, Seppo $u School of Pharmacy, Faculty of Health Sciences, University of Eastern Finland, P.O. Box 1627, FI-70211 Kuopio, Finland
- 700 1_
- $a Hiltunen, Mikko $u Institute of Biomedicine, School of Medicine, University of Eastern Finland, P.O. Box 1627, FI-70211 Kuopio, Finland
- 700 1_
- $a Terasaki, Tetsuya $u School of Pharmacy, Faculty of Health Sciences, University of Eastern Finland, P.O. Box 1627, FI-70211 Kuopio, Finland
- 700 1_
- $a Lehtonen, Marko $u School of Pharmacy, Faculty of Health Sciences, University of Eastern Finland, P.O. Box 1627, FI-70211 Kuopio, Finland
- 700 1_
- $a Jalkanen, Aaro $u School of Pharmacy, Faculty of Health Sciences, University of Eastern Finland, P.O. Box 1627, FI-70211 Kuopio, Finland
- 700 1_
- $a Huttunen, Kristiina M $u School of Pharmacy, Faculty of Health Sciences, University of Eastern Finland, P.O. Box 1627, FI-70211 Kuopio, Finland
- 773 0_
- $w MED00003147 $t Life sciences $x 1879-0631 $g Roč. 310, č. - (2022), s. 121088
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/36257461 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20230120 $b ABA008
- 991 __
- $a 20230131151555 $b ABA008
- 999 __
- $a ok $b bmc $g 1891244 $s 1183700
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2022 $b 310 $c - $d 121088 $e 20221017 $i 1879-0631 $m Life sciences $n Life Sci $x MED00003147
- LZP __
- $a Pubmed-20230120
